BRCA1 and ovarian cancer: As a significant number of ovarian cancer patients harbour germline BRCA1/BRCA2 mutations, a targeted screen for carriers in this defined population has the potential to improve health management of patients and reduce ovarian cancer risk for their mutation-carrier family members.